Exploring the Impact of Efavirenz on Aflatoxin B1 Metabolism: Insights from a Physiologically Based Pharmacokinetic Model and a Human Liver Microsome Study.

MLA

Lootens, Orphélie, et al. “Exploring the Impact of Efavirenz on Aflatoxin B1 Metabolism: Insights from a Physiologically Based Pharmacokinetic Model and a Human Liver Microsome Study.” Toxins, vol. 16, no. 6, June 2024. EBSCOhost, https://doi.org/10.3390/toxins16060259.

APA

Lootens, O., De Boevre, M., Gasthuys, E., De Saeger, S., Van Bocxlaer, J., & Vermeulen, A. (2024). Exploring the Impact of Efavirenz on Aflatoxin B1 Metabolism: Insights from a Physiologically Based Pharmacokinetic Model and a Human Liver Microsome Study. Toxins, 16(6). https://doi.org/10.3390/toxins16060259

Chicago

Lootens, Orphélie, Marthe De Boevre, Elke Gasthuys, Sarah De Saeger, Jan Van Bocxlaer, and An Vermeulen. 2024. “Exploring the Impact of Efavirenz on Aflatoxin B1 Metabolism: Insights from a Physiologically Based Pharmacokinetic Model and a Human Liver Microsome Study.” Toxins 16 (6). doi:10.3390/toxins16060259.